RE:RE:BMS buys stock in TCR-based cell therapies & bispecifics co.Like BMS Big Pharma's M&A targets are increasingly moving towards biological assets, specifically in cancer and immunology, which are granted 13 years of FDA market exclusivity as compared to 9 years exclusivity for small molecules.